Showing results (41-50 of 76) with videos related to
Sort By:
Pageof 8
Neurology|November 20, 2013
Achieving consensus for clinical trials: the REiNS International CollaborationScott R Plotkin, Jaishri O Blakeley, Eva Dombi, et al.Brain : a Journal of Neurology|February 16, 2013
Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cellsRobin D S Doddrell, Xin-Peng Dun, Aditya Shivane, et al.Neuro-Oncology Advances|March 9, 2026
Artificial intelligence pipeline predicts the integrated molecular-morphologic risk score of meningiomas from routine preoperative MRIDamjan Veljanoski, Ali Golbaf, Prutha Chawda, et al.Acta Neuropathologica Communications|December 16, 2023
A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomasLaurien L van de Weijer, Emanuela Ercolano, Ting Zhang, et al.Clinical Trials (London, England)|October 31, 2023
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trialsR Taylor Sundby, Steven D Rhodes, Edina Komlodi-Pasztor, et al.Cancer Research|December 2, 2021
Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and MeningiomaEmmanuel A Maze, Bora Agit, Shona Reeves, et al.Cancer Cell|July 16, 2014
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleusWei Li, Jonathan Cooper, Lu Zhou, et al.The British Journal of Radiology|March 30, 2019
Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncologySamantha J Mills, Mark R Radon, Richard D Baird, et al.Journal of Neurology|March 13, 2014
Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2Rosalie E Ferner, Adam Shaw, D Gareth Evans, et al.International Journal of Molecular Sciences|January 12, 2021
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I MeningiomasAgbolahan A Sofela, David A Hilton, Sylwia Ammoun, et al.Pageof 8